Thursday, October 6, 2011

Scios pleads guilty for misbranding heart failure drug, fined $85M

Scios Inc. has agreed pay an $85 million criminal fine, as it pleaded guilty this week to misbranding a heart-failure drug.
Scios, a Fremont-based subsidiary of Johnson & Johnson (NYSE:JNJ), will pay the fine to the U.S. government as part of a plea agreement. Scios pleaded guilty Wednesday to a misdemeanor for introducing the drug Natrecor for a use that was not approved by the Food and Drug Administration.

No comments:

Post a Comment